ID   PMM2_HUMAN              Reviewed;         246 AA.
AC   O15305; A8K672; B7Z6R0; D3DUF3;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   12-APR-2017, entry version 181.
DE   RecName: Full=Phosphomannomutase 2;
DE            Short=PMM 2;
DE            EC=5.4.2.8;
GN   Name=PMM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS CDG1A.
RX   PubMed=9140401; DOI=10.1038/ng0597-88;
RA   Matthijs G., Schollen E., Pardon E., Veiga-Da-Cunha M., Jaeken J.,
RA   Cassiman J.-J., van Schaftingen E.;
RT   "Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in
RT   carbohydrate-deficient glycoprotein type I syndrome (Jaeken
RT   syndrome).";
RL   Nat. Genet. 16:88-92(1997).
RN   [2]
RP   ERRATUM.
RA   Matthijs G., Schollen E., Pardon E., Veiga-Da-Cunha M., Jaeken J.,
RA   Cassiman J.-J., van Schaftingen E.;
RL   Nat. Genet. 16:316-316(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9425221; DOI=10.1093/hmg/7.2.157;
RA   Schollen E., Pardon E., Heykants L., Renard J., Doggett N.A.,
RA   Callen D.F., Cassiman J.J., Matthijs G.;
RT   "Comparative analysis of the phosphomannomutase genes PMM1, PMM2 and
RT   PMM2psi: the sequence variation in the processed pseudogene is a
RT   reflection of the mutations found in the functional gene.";
RL   Hum. Mol. Genet. 7:157-164(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16540464; DOI=10.1074/jbc.M601505200;
RA   Silvaggi N.R., Zhang C., Lu Z., Dai J., Dunaway-Mariano D.,
RA   Allen K.N.;
RT   "The X-ray crystal structures of human alpha-phosphomannomutase 1
RT   reveal the structural basis of congenital disorder of glycosylation
RT   type 1a.";
RL   J. Biol. Chem. 281:14918-14926(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS).
RX   PubMed=17850744; DOI=10.1016/j.str.2007.06.019;
RA   Levin E.J., Kondrashov D.A., Wesenberg G.E., Phillips G.N. Jr.;
RT   "Ensemble refinement of protein crystal structures: validation and
RT   application.";
RL   Structure 15:1040-1052(2007).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS).
RG   Center for eukaryotic structural genomics (CESG);
RT   "X-ray structure of human phosphomannomutase 2 (PMM2).";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [15]
RP   REVIEW ON VARIANTS CDG1A.
RX   PubMed=10527672; DOI=10.1006/mgme.1999.2914;
RA   Matthijs G., Schollen E., Heykants L., Gruenewald S.;
RT   "Phosphomannomutase deficiency: the molecular basis of the classical
RT   Jaeken syndrome (CDGS type Ia).";
RL   Mol. Genet. Metab. 68:220-226(1999).
RN   [16]
RP   VARIANTS CDG1A.
RX   PubMed=9497260; DOI=10.1086/301763;
RA   Matthijs G., Schollen E., van Schaftingen E., Cassiman J.-J.,
RA   Jaeken J.;
RT   "Lack of homozygotes for the most frequent disease allele in
RT   carbohydrate-deficient glycoprotein syndrome type 1A.";
RL   Am. J. Hum. Genet. 62:542-550(1998).
RN   [17]
RP   VARIANTS CDG1A ARG-117 AND GLU-223.
RX   PubMed=9781039; DOI=10.1038/sj.ejhg.5200194;
RA   Kjaergaard S., Skovby F., Schwartz M.;
RT   "Absence of homozygosity for predominant mutations in PMM2 in Danish
RT   patients with carbohydrate-deficient glycoprotein syndrome type 1.";
RL   Eur. J. Hum. Genet. 6:331-336(1998).
RN   [18]
RP   VARIANTS CDG1A LEU-144; SER-229 AND PRO-238.
RX   PubMed=10066032; DOI=10.1034/j.1399-0004.1999.550109.x;
RA   Kondo I., Mizugishi K., Yoneda Y., Hashimoto T., Kuwajima K.,
RA   Yuasa I., Shigemoto K., Kuroda Y.;
RT   "Missense mutations in phosphomannomutase 2 gene in two Japanese
RT   families with carbohydrate-deficient glycoprotein syndrome type 1.";
RL   Clin. Genet. 55:50-54(1999).
RN   [19]
RP   VARIANT CDG1A GLY-192, AND CHARACTERIZATION OF VARIANTS CDG1A ARG-117;
RP   LEU-119; HIS-141; GLY-192; GLU-223 AND ARG-237.
RX   PubMed=10602363; DOI=10.1038/sj.ejhg.5200398;
RA   Kjaergaard S., Skovby F., Schwartz M.;
RT   "Carbohydrate-deficient glycoprotein syndrome type 1A: expression and
RT   characterisation of wild type and mutant PMM2 in E. coli.";
RL   Eur. J. Hum. Genet. 7:884-888(1999).
RN   [20]
RP   VARIANTS CDG1A LYS-139 AND HIS-141.
RX   PubMed=10571956;
RX   DOI=10.1002/(SICI)1098-1004(199912)14:6<543::AID-HUMU17>3.3.CO;2-J;
RA   Vuillaumier-Barrot S., Barnier A., Cuer M., Durand G., Grandchamp B.,
RA   Seta N.;
RT   "Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-
RT   deficient glycoprotein syndrome type Ia disrupting a splicing enhancer
RT   resulting in exon 5 skipping.";
RL   Hum. Mutat. 14:543-544(1999).
RN   [21]
RP   VARIANTS CDG1A TYR-9; CYS-11; ARG-32; ALA-44; TYR-65; MET-67; SER-69;
RP   CYS-76; LYS-101; PHE-103; CYS-106; VAL-108; LEU-113; ARG-117; LEU-119;
RP   THR-120; GLN-123; MET-129; ALA-131; ASN-132; THR-132; LYS-139;
RP   HIS-141; ASN-148; GLY-151; THR-153; SER-157; TRP-162; VAL-172;
RP   ARG-175; SER-183; GLY-185; GLY-188; GLY-192; ARG-195; ALA-197;
RP   SER-206; ALA-208; ILE-216; SER-216; GLU-217; LEU-218; GLU-223;
RP   SER-226; ARG-228; CYS-228; SER-229; MET-231; THR-233; ARG-237;
RP   MET-237; GLY-238 AND SER-241.
RX   PubMed=11058895;
RX   DOI=10.1002/1098-1004(200011)16:5<386::AID-HUMU2>3.0.CO;2-Y;
RA   Matthijs G., Schollen E., Bjursell C., Erlandson A., Freeze H.,
RA   Imtiaz F., Kjaergaard S., Martinsson T., Schwartz M., Seta N.,
RA   Vuillaumier-Barrot S., Westphal V., Winchester B.;
RT   "Mutations in PMM2 that cause congenital disorders of glycosylation,
RT   type Ia (CDG-Ia).";
RL   Hum. Mutat. 16:386-394(2000).
RN   [22]
RP   VARIANTS CDG1A TYR-9; CYS-11; MET-67; LEU-113; ARG-117; LEU-119;
RP   GLN-123; MET-129; HIS-141; VAL-172; ARG-175; SER-183; GLY-185;
RP   GLY-192; SER-216; GLU-217; GLU-223; ARG-228; MET-231 AND ARG-237.
RX   PubMed=11058896;
RX   DOI=10.1002/1098-1004(200011)16:5<395::AID-HUMU3>3.0.CO;2-T;
RA   Bjursell C., Erlandson A., Nordling M., Nilsson S., Wahlstroem J.,
RA   Stibler H., Kristiansson B., Martinsson T.;
RT   "PMM2 mutation spectrum, including 10 novel mutations, in a large CDG
RT   type 1A family material with a focus on Scandinavian families.";
RL   Hum. Mutat. 16:395-400(2000).
RN   [23]
RP   VARIANTS CDG1A LEU-119; ASN-132; HIS-141; ASN-148; SER-183; ALA-208;
RP   MET-231 AND MET-237.
RX   PubMed=10801058; DOI=10.1023/A:1005669900330;
RA   Imtiaz F., Worthington V., Champion M., Beesley C., Charlwood J.,
RA   Clayton P., Keir G., Mian N., Winchester B.;
RT   "Genotypes and phenotypes of patients in the UK with carbohydrate-
RT   deficient glycoprotein syndrome type 1.";
RL   J. Inherit. Metab. Dis. 23:162-174(2000).
RN   [24]
RP   VARIANT CDG1A VAL-104.
RX   PubMed=11350185; DOI=10.1006/mgme.2001.3174;
RA   Westphal V., Enns G.M., McCracken M.F., Freeze H.H.;
RT   "Functional analysis of novel mutations in a congenital disorder of
RT   glycosylation Ia patient with mixed Asian ancestry.";
RL   Mol. Genet. Metab. 73:71-76(2001).
RN   [25]
RP   VARIANTS CDG1A GLU-15; CYS-64; ALA-93; SER-214 AND ASN-223, AND
RP   VARIANT ARG-42.
RX   PubMed=12357336; DOI=10.1038/sj.ejhg.5200858;
RA   Schollen E., Martens K., Geuzens E., Matthijs G.;
RT   "DHPLC analysis as a platform for molecular diagnosis of congenital
RT   disorders of glycosylation (CDG).";
RL   Eur. J. Hum. Genet. 10:643-648(2002).
RN   [26]
RP   VARIANTS CDG1A TYR-9; SER-20; ARG-32; HIS-37; LEU-44; TYR-65; SER-69;
RP   PHE-103; VAL-108; LEU-113; LEU-119; GLN-123; MET-129; ALA-131;
RP   THR-132; PHE-132; LYS-139; CYS-141; HIS-141; THR-153; SER-157;
RP   TRP-162; VAL-176; HIS-177; ALA-197; SER-214; SER-226; MET-231;
RP   ARG-237; MET-237 AND SER-241, VARIANT ARG-42, AND CHARACTERIZATION OF
RP   VARIANTS CDG1A SER-20; HIS-37; PHE-132; LYS-139; CYS-141; HIS-141;
RP   VAL-176 AND HIS-177.
RX   PubMed=15844218; DOI=10.1002/humu.9336;
RA   Le Bizec C., Vuillaumier-Barrot S., Barnier A., Dupre T., Durand G.,
RA   Seta N.;
RT   "A new insight into PMM2 mutations in the French population.";
RL   Hum. Mutat. 25:504-505(2005).
RN   [27]
RP   VARIANTS CDG1A ALA-44 AND MET-231.
RX   PubMed=17307006; DOI=10.1016/j.ymgme.2007.01.003;
RA   Schollen E., Keldermans L., Foulquier F., Briones P., Chabas A.,
RA   Sanchez-Valverde F., Adamowicz M., Pronicka E., Wevers R.,
RA   Matthijs G.;
RT   "Characterization of two unusual truncating PMM2 mutations in two CDG-
RT   Ia patients.";
RL   Mol. Genet. Metab. 90:408-413(2007).
CC   -!- FUNCTION: Involved in the synthesis of the GDP-mannose and
CC       dolichol-phosphate-mannose required for a number of critical
CC       mannosyl transfer reactions. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Alpha-D-mannose 1-phosphate = D-mannose 6-
CC       phosphate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=16 uM for alpha-D-mannose 1-phosphate
CC         {ECO:0000269|PubMed:16540464};
CC         KM=13.5 uM for alpha-D-glucose 1-phosphate
CC         {ECO:0000269|PubMed:16540464};
CC   -!- PATHWAY: Nucleotide-sugar biosynthesis; GDP-alpha-D-mannose
CC       biosynthesis; alpha-D-mannose 1-phosphate from D-fructose 6-
CC       phosphate: step 2/2.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q96HD9:ACY3; NbExp=5; IntAct=EBI-10182608, EBI-3916242;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15305-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15305-2; Sequence=VSP_056228, VSP_056229;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Congenital disorder of glycosylation 1A (CDG1A)
CC       [MIM:212065]: A form of congenital disorder of glycosylation, a
CC       multisystem disorder caused by a defect in glycoprotein
CC       biosynthesis and characterized by under-glycosylated serum
CC       glycoproteins. Congenital disorders of glycosylation result in a
CC       wide variety of clinical features, such as defects in the nervous
CC       system development, psychomotor retardation, dysmorphic features,
CC       hypotonia, coagulation disorders, and immunodeficiency. The broad
CC       spectrum of features reflects the critical role of N-glycoproteins
CC       during embryonic development, differentiation, and maintenance of
CC       cell functions. CDG1A is an autosomal recessive disorder
CC       characterized by a severe encephalopathy with axial hypotonia,
CC       abnormal eye movement, and pronounced psychomotor retardation, as
CC       well as peripheral neuropathy, cerebellar hypoplasia, and
CC       retinitis pigmentosa. Patients show a peculiar distribution of
CC       subcutaneous fat, nipple retraction, and hypogonadism.
CC       {ECO:0000269|PubMed:10066032, ECO:0000269|PubMed:10527672,
CC       ECO:0000269|PubMed:10571956, ECO:0000269|PubMed:10602363,
CC       ECO:0000269|PubMed:10801058, ECO:0000269|PubMed:11058895,
CC       ECO:0000269|PubMed:11058896, ECO:0000269|PubMed:11350185,
CC       ECO:0000269|PubMed:12357336, ECO:0000269|PubMed:15844218,
CC       ECO:0000269|PubMed:17307006, ECO:0000269|PubMed:9140401,
CC       ECO:0000269|PubMed:9497260, ECO:0000269|PubMed:9781039}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the eukaryotic PMM family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U85773; AAC51368.1; -; mRNA.
DR   EMBL; AF157796; AAD45895.1; -; Genomic_DNA.
DR   EMBL; AF157790; AAD45895.1; JOINED; Genomic_DNA.
DR   EMBL; AF157791; AAD45895.1; JOINED; Genomic_DNA.
DR   EMBL; AF157792; AAD45895.1; JOINED; Genomic_DNA.
DR   EMBL; AF157793; AAD45895.1; JOINED; Genomic_DNA.
DR   EMBL; AF157794; AAD45895.1; JOINED; Genomic_DNA.
DR   EMBL; AF157795; AAD45895.1; JOINED; Genomic_DNA.
DR   EMBL; AK291537; BAF84226.1; -; mRNA.
DR   EMBL; AK300785; BAH13346.1; -; mRNA.
DR   EMBL; AC012173; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471112; EAW85200.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85201.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85202.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85203.1; -; Genomic_DNA.
DR   EMBL; BC008310; AAH08310.1; -; mRNA.
DR   CCDS; CCDS10536.1; -. [O15305-1]
DR   RefSeq; NP_000294.1; NM_000303.2. [O15305-1]
DR   UniGene; Hs.625732; -.
DR   PDB; 2AMY; X-ray; 2.09 A; A=2-246.
DR   PDB; 2Q4R; X-ray; 2.09 A; A=2-246.
DR   PDBsum; 2AMY; -.
DR   PDBsum; 2Q4R; -.
DR   ProteinModelPortal; O15305; -.
DR   SMR; O15305; -.
DR   BioGrid; 111386; 5.
DR   IntAct; O15305; 4.
DR   STRING; 9606.ENSP00000268261; -.
DR   BindingDB; O15305; -.
DR   ChEMBL; CHEMBL1741162; -.
DR   iPTMnet; O15305; -.
DR   PhosphoSitePlus; O15305; -.
DR   BioMuta; PMM2; -.
DR   EPD; O15305; -.
DR   MaxQB; O15305; -.
DR   PaxDb; O15305; -.
DR   PeptideAtlas; O15305; -.
DR   PRIDE; O15305; -.
DR   DNASU; 5373; -.
DR   Ensembl; ENST00000268261; ENSP00000268261; ENSG00000140650. [O15305-1]
DR   Ensembl; ENST00000566604; ENSP00000456774; ENSG00000140650. [O15305-2]
DR   GeneID; 5373; -.
DR   KEGG; hsa:5373; -.
DR   UCSC; uc002czf.5; human. [O15305-1]
DR   CTD; 5373; -.
DR   DisGeNET; 5373; -.
DR   GeneCards; PMM2; -.
DR   GeneReviews; PMM2; -.
DR   HGNC; HGNC:9115; PMM2.
DR   HPA; HPA040852; -.
DR   HPA; HPA063649; -.
DR   MalaCards; PMM2; -.
DR   MIM; 212065; phenotype.
DR   MIM; 601785; gene.
DR   neXtProt; NX_O15305; -.
DR   OpenTargets; ENSG00000140650; -.
DR   Orphanet; 79318; PMM2-CDG.
DR   PharmGKB; PA33441; -.
DR   eggNOG; KOG3189; Eukaryota.
DR   eggNOG; COG0561; LUCA.
DR   GeneTree; ENSGT00390000002918; -.
DR   HOGENOM; HOG000181843; -.
DR   HOVERGEN; HBG009971; -.
DR   InParanoid; O15305; -.
DR   KO; K17497; -.
DR   OMA; ITKEMDG; -.
DR   OrthoDB; EOG091G0J2S; -.
DR   PhylomeDB; O15305; -.
DR   TreeFam; TF300874; -.
DR   BRENDA; 5.4.2.8; 2681.
DR   Reactome; R-HSA-446205; Synthesis of GDP-mannose.
DR   SABIO-RK; O15305; -.
DR   UniPathway; UPA00126; UER00424.
DR   ChiTaRS; PMM2; human.
DR   EvolutionaryTrace; O15305; -.
DR   GeneWiki; PMM2; -.
DR   GenomeRNAi; 5373; -.
DR   PRO; PR:O15305; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000140650; -.
DR   CleanEx; HS_PMM2; -.
DR   ExpressionAtlas; O15305; baseline and differential.
DR   Genevisible; O15305; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0004615; F:phosphomannomutase activity; IBA:GO_Central.
DR   GO; GO:0009298; P:GDP-mannose biosynthetic process; TAS:Reactome.
DR   GO; GO:0006013; P:mannose metabolic process; IBA:GO_Central.
DR   GO; GO:0006486; P:protein glycosylation; TAS:ProtInc.
DR   GO; GO:0006487; P:protein N-linked glycosylation; IBA:GO_Central.
DR   GO; GO:0045047; P:protein targeting to ER; IBA:GO_Central.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR023214; HAD-like_dom.
DR   InterPro; IPR006379; HAD-SF_hydro_IIB.
DR   InterPro; IPR005002; PMM.
DR   PANTHER; PTHR10466; PTHR10466; 1.
DR   Pfam; PF03332; PMM; 1.
DR   SFLD; SFLDG01143; C2.B.3:_Phosphomannomutase_Lik; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   TIGRFAMs; TIGR01484; HAD-SF-IIB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Congenital disorder of glycosylation; Cytoplasm; Disease mutation;
KW   Isomerase; Polymorphism; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    246       Phosphomannomutase 2.
FT                                /FTId=PRO_0000199694.
FT   ACT_SITE     12     12       Nucleophile. {ECO:0000250}.
FT   ACT_SITE     14     14       Proton donor/acceptor. {ECO:0000255}.
FT   BINDING      21     21       Substrate. {ECO:0000250}.
FT   BINDING     123    123       Substrate. {ECO:0000250}.
FT   BINDING     134    134       Substrate. {ECO:0000250}.
FT   BINDING     141    141       Substrate. {ECO:0000250}.
FT   BINDING     179    179       Substrate. {ECO:0000250}.
FT   BINDING     181    181       Substrate. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     149    149       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9Z2M7}.
FT   VAR_SEQ     117    119       GTF -> KKI (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056228.
FT   VAR_SEQ     120    246       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056229.
FT   VARIANT       9      9       C -> Y (in CDG1A; dbSNP:rs104894532).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022469.
FT   VARIANT      11     11       F -> C (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022470.
FT   VARIANT      15     15       G -> E (in CDG1A).
FT                                {ECO:0000269|PubMed:12357336}.
FT                                /FTId=VAR_022471.
FT   VARIANT      20     20       P -> S (in CDG1A; reduction of activity).
FT                                {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022472.
FT   VARIANT      32     32       L -> R (in CDG1A; dbSNP:rs398123312).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022473.
FT   VARIANT      37     37       Q -> H (in CDG1A; partial loss of
FT                                activity). {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022474.
FT   VARIANT      37     37       Q -> L (in dbSNP:rs2304472).
FT                                /FTId=VAR_022133.
FT   VARIANT      42     42       G -> R (in dbSNP:rs755402538).
FT                                {ECO:0000269|PubMed:12357336,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022475.
FT   VARIANT      44     44       V -> A (in CDG1A; dbSNP:rs104894534).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:17307006}.
FT                                /FTId=VAR_006093.
FT   VARIANT      44     44       V -> L (in CDG1A).
FT                                {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022563.
FT   VARIANT      64     64       Y -> C (in CDG1A).
FT                                {ECO:0000269|PubMed:12357336}.
FT                                /FTId=VAR_022476.
FT   VARIANT      65     65       D -> Y (in CDG1A; dbSNP:rs104894527).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006094.
FT   VARIANT      67     67       V -> M (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022477.
FT   VARIANT      69     69       P -> S (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022478.
FT   VARIANT      76     76       Y -> C (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022479.
FT   VARIANT      93     93       E -> A (in CDG1A).
FT                                {ECO:0000269|PubMed:12357336}.
FT                                /FTId=VAR_022480.
FT   VARIANT     101    101       N -> K (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006095.
FT   VARIANT     103    103       C -> F (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022481.
FT   VARIANT     104    104       L -> V (in CDG1A; dbSNP:rs770458492).
FT                                {ECO:0000269|PubMed:11350185}.
FT                                /FTId=VAR_012344.
FT   VARIANT     106    106       Y -> C (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006096.
FT   VARIANT     108    108       A -> V (in CDG1A; dbSNP:rs200503569).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006097.
FT   VARIANT     113    113       P -> L (in CDG1A; dbSNP:rs80338700).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006098.
FT   VARIANT     117    117       G -> R (in CDG1A; loss of activity;
FT                                dbSNP:rs104894530).
FT                                {ECO:0000269|PubMed:10602363,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:9781039}.
FT                                /FTId=VAR_006099.
FT   VARIANT     119    119       F -> L (in CDG1A; partial loss of
FT                                activity; dbSNP:rs80338701).
FT                                {ECO:0000269|PubMed:10602363,
FT                                ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006100.
FT   VARIANT     120    120       I -> T (in CDG1A; dbSNP:rs368582085).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022482.
FT   VARIANT     123    123       R -> Q (in CDG1A; dbSNP:rs141498002).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006101.
FT   VARIANT     129    129       V -> M (in CDG1A; dbSNP:rs28938475).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006102.
FT   VARIANT     131    131       P -> A (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006103.
FT   VARIANT     132    132       I -> F (in CDG1A; slightly reduced
FT                                activity; dbSNP:rs753632453).
FT                                {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022483.
FT   VARIANT     132    132       I -> N (in CDG1A).
FT                                {ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022484.
FT   VARIANT     132    132       I -> T (in CDG1A; dbSNP:rs80338702).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006104.
FT   VARIANT     139    139       E -> K (in CDG1A; this mutation seems to
FT                                disrupt a splicing enhancer sequence and
FT                                thus results in most cases in a protein
FT                                with exon 5 skipped; slightly reduced
FT                                activity; dbSNP:rs80338703).
FT                                {ECO:0000269|PubMed:10571956,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_009232.
FT   VARIANT     141    141       R -> C (in CDG1A; loss of activity;
FT                                dbSNP:rs746610168).
FT                                {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022485.
FT   VARIANT     141    141       R -> H (in CDG1A; frequent mutation; loss
FT                                of activity; observed in heterozygous
FT                                patients; homozygosis of this mutation is
FT                                incompatible with life;
FT                                dbSNP:rs28936415).
FT                                {ECO:0000269|PubMed:10571956,
FT                                ECO:0000269|PubMed:10602363,
FT                                ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006105.
FT   VARIANT     144    144       F -> L (in CDG1A; dbSNP:rs150719105).
FT                                {ECO:0000269|PubMed:10066032}.
FT                                /FTId=VAR_022486.
FT   VARIANT     148    148       D -> N (in CDG1A; dbSNP:rs148032587).
FT                                {ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022487.
FT   VARIANT     151    151       E -> G (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022488.
FT   VARIANT     153    153       I -> T (in CDG1A; dbSNP:rs150577656).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022489.
FT   VARIANT     157    157       F -> S (in CDG1A; dbSNP:rs190521996).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022490.
FT   VARIANT     162    162       R -> W (in CDG1A; dbSNP:rs104894526).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006106.
FT   VARIANT     172    172       F -> V (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022491.
FT   VARIANT     175    175       G -> R (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_006107.
FT   VARIANT     176    176       G -> V (in CDG1A; loss of activity).
FT                                {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022492.
FT   VARIANT     177    177       Q -> H (in CDG1A; partial loss of
FT                                activity). {ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022493.
FT   VARIANT     183    183       F -> S (in CDG1A; dbSNP:rs780581250).
FT                                {ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022494.
FT   VARIANT     185    185       D -> G (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022495.
FT   VARIANT     188    188       D -> G (in CDG1A; severe;
FT                                dbSNP:rs80338704).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006108.
FT   VARIANT     192    192       C -> G (in CDG1A; normal activity but
FT                                lower affinity for alpha-D-mannose 1-
FT                                phosphate). {ECO:0000269|PubMed:10602363,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022496.
FT   VARIANT     195    195       H -> R (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022497.
FT   VARIANT     197    197       E -> A (in CDG1A; dbSNP:rs34258285).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022498.
FT   VARIANT     206    206       F -> S (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022499.
FT   VARIANT     208    208       G -> A (in CDG1A; dbSNP:rs398123309).
FT                                {ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006109.
FT   VARIANT     212    212       M -> V (in dbSNP:rs3743808).
FT                                /FTId=VAR_022134.
FT   VARIANT     214    214       G -> S (in CDG1A).
FT                                {ECO:0000269|PubMed:12357336,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022500.
FT   VARIANT     216    216       N -> I (in CDG1A; dbSNP:rs78290141).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006110.
FT   VARIANT     216    216       N -> S (in CDG1A; dbSNP:rs78290141).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022501.
FT   VARIANT     217    217       D -> E (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022502.
FT   VARIANT     218    218       H -> L (in CDG1A; dbSNP:rs80338705).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022503.
FT   VARIANT     223    223       D -> E (in CDG1A; normal activity but
FT                                lower affinity for alpha-D-mannose 1-
FT                                phosphate; dbSNP:rs104894531).
FT                                {ECO:0000269|PubMed:10602363,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:9781039}.
FT                                /FTId=VAR_006111.
FT   VARIANT     223    223       D -> N (in CDG1A; dbSNP:rs201960869).
FT                                {ECO:0000269|PubMed:12357336}.
FT                                /FTId=VAR_022504.
FT   VARIANT     226    226       T -> S (in CDG1A; dbSNP:rs80338706).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022505.
FT   VARIANT     228    228       G -> C (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022506.
FT   VARIANT     228    228       G -> R (in CDG1A; dbSNP:rs558826439).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896}.
FT                                /FTId=VAR_022507.
FT   VARIANT     229    229       Y -> S (in CDG1A; dbSNP:rs398123311).
FT                                {ECO:0000269|PubMed:10066032,
FT                                ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006112.
FT   VARIANT     231    231       V -> M (in CDG1A; dbSNP:rs80338707).
FT                                {ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218,
FT                                ECO:0000269|PubMed:17307006}.
FT                                /FTId=VAR_006113.
FT   VARIANT     233    233       A -> T (in CDG1A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_006114.
FT   VARIANT     237    237       T -> M (in CDG1A; dbSNP:rs80338708).
FT                                {ECO:0000269|PubMed:10801058,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_006115.
FT   VARIANT     237    237       T -> R (in CDG1A; loss of activity;
FT                                dbSNP:rs80338708).
FT                                {ECO:0000269|PubMed:10602363,
FT                                ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:11058896,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022508.
FT   VARIANT     238    238       R -> G (in CDG1A).
FT                                {ECO:0000269|PubMed:11058895}.
FT                                /FTId=VAR_022509.
FT   VARIANT     238    238       R -> P (in CDG1A; dbSNP:rs151319324).
FT                                {ECO:0000269|PubMed:10066032}.
FT                                /FTId=VAR_006116.
FT   VARIANT     241    241       C -> S (in CDG1A; dbSNP:rs80338709).
FT                                {ECO:0000269|PubMed:11058895,
FT                                ECO:0000269|PubMed:15844218}.
FT                                /FTId=VAR_022510.
FT   STRAND        6     14       {ECO:0000244|PDB:2AMY}.
FT   TURN         15     17       {ECO:0000244|PDB:2AMY}.
FT   HELIX        26     35       {ECO:0000244|PDB:2AMY}.
FT   TURN         36     38       {ECO:0000244|PDB:2AMY}.
FT   STRAND       39     44       {ECO:0000244|PDB:2AMY}.
FT   HELIX        49     56       {ECO:0000244|PDB:2AMY}.
FT   HELIX        60     63       {ECO:0000244|PDB:2AMY}.
FT   STRAND       65     69       {ECO:0000244|PDB:2AMY}.
FT   HELIX        70     72       {ECO:0000244|PDB:2AMY}.
FT   STRAND       74     77       {ECO:0000244|PDB:2AMY}.
FT   STRAND       80     84       {ECO:0000244|PDB:2AMY}.
FT   HELIX        87     91       {ECO:0000244|PDB:2AMY}.
FT   HELIX        93    109       {ECO:0000244|PDB:2AMY}.
FT   STRAND      119    123       {ECO:0000244|PDB:2AMY}.
FT   STRAND      126    129       {ECO:0000244|PDB:2AMY}.
FT   HELIX       138    151       {ECO:0000244|PDB:2AMY}.
FT   HELIX       153    164       {ECO:0000244|PDB:2AMY}.
FT   TURN        165    167       {ECO:0000244|PDB:2AMY}.
FT   STRAND      170    175       {ECO:0000244|PDB:2AMY}.
FT   TURN        176    178       {ECO:0000244|PDB:2AMY}.
FT   STRAND      179    184       {ECO:0000244|PDB:2AMY}.
FT   HELIX       189    195       {ECO:0000244|PDB:2AMY}.
FT   TURN        196    198       {ECO:0000244|PDB:2AMY}.
FT   STRAND      202    208       {ECO:0000244|PDB:2AMY}.
FT   HELIX       219    222       {ECO:0000244|PDB:2AMY}.
FT   STRAND      226    230       {ECO:0000244|PDB:2AMY}.
FT   HELIX       234    244       {ECO:0000244|PDB:2AMY}.
SQ   SEQUENCE   246 AA;  28082 MW;  29F1D5B9539B6221 CRC64;
     MAAPGPALCL FDVDGTLTAP RQKITKEMDD FLQKLRQKIK IGVVGGSDFE KVQEQLGNDV
     VEKYDYVFPE NGLVAYKDGK LLCRQNIQSH LGEALIQDLI NYCLSYIAKI KLPKKRGTFI
     EFRNGMLNVS PIGRSCSQEE RIEFYELDKK ENIRQKFVAD LRKEFAGKGL TFSIGGQISF
     DVFPDGWDKR YCLRHVENDG YKTIYFFGDK TMPGGNDHEI FTDPRTMGYS VTAPEDTRRI
     CELLFS
//
